Cargando…

Clinicopathological values of PD-L1 expression in HER2-positive breast cancer

Several ongoing clinical trials are investigating the use of immuno-targeting therapy with programmed cell death protein-1 and programmed death-ligand 1 (PD-L1) inhibitors for triple-negative breast cancer. However, the role of PD-L1 expression in HER2-positive breast cancer remains unclear. We inve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kurozumi, Sasagu, Inoue, Kenichi, Matsumoto, Hiroshi, Fujii, Takaaki, Horiguchi, Jun, Oyama, Tetsunari, Kurosumi, Masafumi, Shirabe, Ken
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853939/ https://www.ncbi.nlm.nih.gov/pubmed/31723167 http://dx.doi.org/10.1038/s41598-019-52944-6

Ejemplares similares

Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

Prognostic significance of tumour-infiltrating lymphocytes for oestrogen receptor-negative breast cancer without lymph node metastasis
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2018)

Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab
por: Kurozumi, Sasagu, et al.
Publicado: (2015)

Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index
por: Kurozumi, Sasagu, et al.
Publicado: (2017)

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
por: Kurozumi, Sasagu, et al.
Publicado: (2016)

Prognostic value of the ubiquitin ligase carboxyl terminus of the Hsc70‐interacting protein in postmenopausal breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2016)

Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2021)

The pathological complete response and secreted protein acidic and rich in cysteine expression in patients with breast cancer receiving neoadjuvant nab-paclitaxel chemotherapy
por: Nakazawa, Yuko, et al.
Publicado: (2020)

Prognostic value of tumor-infiltrating lymphocytes in estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer
por: Honda, Chikako, et al.
Publicado: (2021)

Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2022)

Phase II study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer
por: Yanai, Keiko, et al.
Publicado: (2020)

Carboxypeptidase A4 accumulation is associated with an aggressive phenotype and poor prognosis in triple-negative breast cancer
por: Handa, Tadashi, et al.
Publicado: (2019)

Diagnostic value of (18)F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8(+)tumour-infiltrating lymphocytes in oral squamous cell carcinoma
por: Togo, Maria, et al.
Publicado: (2020)

Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer
por: Katayama, Ayaka, et al.
Publicado: (2021)

Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators
por: Inoue, Kenichi, et al.
Publicado: (2018)

RNA‐sequence‐based microRNA expression signature in breast cancer: tumor‐suppressive miR‐101‐5p regulates molecular pathogenesis
por: Toda, Hiroko, et al.
Publicado: (2019)

Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets
por: Kurozumi, Sasagu, et al.
Publicado: (2020)

Fibrocystic breast disease with pleomorphic calcifications and segmental distribution: A case report
por: JiueLan, Kuo, et al.
Publicado: (2023)

Clinicopathological study of a dimorphic variant of breast carcinoma
por: Ueno, Nozomi, et al.
Publicado: (2017)

Clinicopathologic characteristics of HER2-positive pure mucinous carcinoma of the breast
por: Jang, Yunjeong, et al.
Publicado: (2020)

Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
por: Nakajima, Hiromichi, et al.
Publicado: (2022)

Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
por: Yang, Liu, et al.
Publicado: (2022)

HER2 Positive and HER2 Negative Classical Type Invasive Lobular Carcinomas: Comparison of Clinicopathologic Features
por: He, Lin, et al.
Publicado: (2021)

HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens
por: Tsuda, Hitoshi, et al.
Publicado: (2010)

Immunological profiles of the breast cancer microenvironment represented by tumor-infiltrating lymphocytes and PD-L1 expression
por: Hanamura, Toru, et al.
Publicado: (2022)

Her2-Positive and Microsatellite Instability Status in Gastric Cancer—Clinicopathological Implications
por: Bermúdez, Ana, et al.
Publicado: (2021)

Association of tumor size in pathological T4 colorectal cancer with desmoplastic reaction and prognosis
por: Shiraishi, Takuya, et al.
Publicado: (2022)

Cytoplasmic localization of connexin 26 suppresses transition of β‐catenin into the nucleus in intestinal‐ and mix‐type gastric cancer
por: Nakazawa, Nobuhiro, et al.
Publicado: (2022)

Evaluation of HER2 Positivity Based on Clinicopathological Findings in HER2 Borderline Tumors in Iranian Patients with Breast Cancer
por: Omranipour, Ramesh, et al.
Publicado: (2023)

Inflammatory and immune checkpoint markers are associated with the severity of aortic stenosis
por: Erkhem-Ochir, Bilguun, et al.
Publicado: (2020)

Clinicopathological factors associated with HER2-positive gastric cancer: A meta-analysis
por: Wang, Hong-Bo, et al.
Publicado: (2017)

Clinicopathological features and Borrmann classification associated with HER2-positive in primary gastric cancer
por: Dai, Xiaomin, et al.
Publicado: (2019)

Aberrant Expression of pRb, p16, p14ARF, MDM2, p21 and p53 in Squamous Cell Carcinomas of Lung
por: Xue, Qi, et al.
Publicado: (2001)

Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy
por: Takada, Mamoru, et al.
Publicado: (2013)

Integrative assessment of clinicopathological parameters and the expression of PD-L1, PD-L2 and PD-1 in tumor cells of retroperitoneal sarcoma
por: Miyake, Makito, et al.
Publicado: (2020)

Evaluation of the Interobserver Agreement in the Number of Mitotic Figures Breast Carcinoma as Simulation of Quality Monitoring in the Japan National Surgical Adjuvant Study of Breast Cancer (NSAS‐BC) Protocol
por: Tsuda, Hitoshi, et al.
Publicado: (2000)

Clinicopathological factors associated with HER2-positive gastric cancer: A meta-analysis: Erratum
Publicado: (2017)

Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis
por: Ding, Xiangli, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_f4rmccri1529umpgmig7pgfrqh